Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes

F. Boccardo; A. Cavo; E. Zanardi; C. Fabbroni; L. Zinoli; A. Di Meglio; E. Arboscello; A. Bellodi; P. Spallarossa; C. Cattrini; C. Messina; A. Rubagotti

doi:10.1093/annonc/mdx423.016

Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes

F. Boccardo, A. Cavo, E. Zanardi, C. Fabbroni, L. Zinoli, A. Di Meglio, E. Arboscello, A. Bellodi, P. Spallarossa, C. Cattrini, C. Messina, A. Rubagotti

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	vi22
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Volume	28
DOIs	https://doi.org/10.1093/annonc/mdx423.016
Publication status	Published - Oct 1 2017

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1093/annonc/mdx423.016

Cite this

Boccardo, F., Cavo, A., Zanardi, E., Fabbroni, C., Zinoli, L., Di Meglio, A., Arboscello, E., Bellodi, A., Spallarossa, P., Cattrini, C., Messina, C., & Rubagotti, A. (2017). Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes. Annals of oncology : official journal of the European Society for Medical Oncology, 28, vi22. https://doi.org/10.1093/annonc/mdx423.016

Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC) : a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes. / Boccardo, F.; Cavo, A.; Zanardi, E. et al.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, 01.10.2017, p. vi22.

Research output: Contribution to journal › Article › peer-review

Boccardo, F, Cavo, A, Zanardi, E, Fabbroni, C, Zinoli, L, Di Meglio, A, Arboscello, E, Bellodi, A, Spallarossa, P, Cattrini, C, Messina, C & Rubagotti, A 2017, 'Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 28, pp. vi22. https://doi.org/10.1093/annonc/mdx423.016

Boccardo F, Cavo A, Zanardi E, Fabbroni C, Zinoli L, Di Meglio A et al. Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Oct 1;28:vi22. https://doi.org/10.1093/annonc/mdx423.016

Boccardo, F. ; Cavo, A. ; Zanardi, E. et al. / Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC) : a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2017 ; Vol. 28. pp. vi22.

@article{1908fe3829594c1184384a903633e9cf,

title = "Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes",

author = "F. Boccardo and A. Cavo and E. Zanardi and C. Fabbroni and L. Zinoli and {Di Meglio}, A. and E. Arboscello and A. Bellodi and P. Spallarossa and C. Cattrini and C. Messina and A. Rubagotti",

year = "2017",

month = oct,

day = "1",

doi = "10.1093/annonc/mdx423.016",

language = "English",

volume = "28",

pages = "vi22",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "NLM (Medline)",

}

TY - JOUR

T1 - Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC)

T2 - a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes

AU - Boccardo, F.

AU - Cavo, A.

AU - Zanardi, E.

AU - Fabbroni, C.

AU - Zinoli, L.

AU - Di Meglio, A.

AU - Arboscello, E.

AU - Bellodi, A.

AU - Spallarossa, P.

AU - Cattrini, C.

AU - Messina, C.

AU - Rubagotti, A.

PY - 2017/10/1

Y1 - 2017/10/1

UR - http://www.scopus.com/inward/record.url?scp=85083544163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85083544163&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx423.016

DO - 10.1093/annonc/mdx423.016

M3 - Article

C2 - 31962634

VL - 28

SP - vi22

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -

Abiraterone acetate (AA) in pre- and post-docetaxel (DX) setting for metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular events and on their impact on clinical outcomes

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this